Financial Times FT.com

Lilly's Zypreza, Pfizer's Geodon could see reimbursement restrictions next year

By Beth Herskovits in New York

Published: December 30 2007 06:12 | Last updated: December 30 2007 06:12

Email options

The information entered on this page will not be used to send unsolicited email, and will not be sold to a 3rd party.Terms of use |Privacy policy

* required fields



(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)